Lorenza Rimassa· @LorenzaRimassa · X·· 14 小时前评分70
正文 · 原文
HARMONi-GI1: ivonescimab + chemo vs durvalumab + chemo in first-line advanced #BTC
-OS 14.9 vs 12.1 mos
-PFS 8.4 vs 5.8 mos
-ORR 53.8 vs 32.5%
A new standard of care in China. Do we need a trial in Western countries?
#ESMO26
#ESMOAmbassadors @myESMO
14 浏览 · 0 赞 · 0 转发 · 0 回复
The PD-1/VEGF bispecific antibody ivonescimab plus chemotherapy significantly improved overall survival in #BiliaryTractCancer in the phase III HARMONi-GI1 #ClinicalTrial presented in a Presidential Symposium at #ESMO26. Read more: 🔗 https://ow.ly/YtKV50ZZGRl #InsightsbyESMO在 X 查看被引用的帖子
来源：Lorenza Rimassa · x.com